RUTHERFORD, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that safety and performance data from its first-in-human trial of its long-term continuous blood glucose monitoring (CBGM) system will be presented at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes (ATTD).

新泽西州鲁瑟福，2025年3月19日（环球新闻社）——专注于为糖尿病患者设计、开发和商业化新型技术的医疗设备公司Glucotrack, Inc.（纳斯达克股票代码：GCTK）今日宣布，其长期连续血糖监测（CBGM）系统首次人体试验的安全性和性能数据将在2025年国际先进技术和糖尿病治疗大会（ATTD）上公布。

ATTD is an important global conference focused on technological innovations in diabetes care. The conference will be held in Amsterdam, the Netherlands, taking place March 19 – 22, 2025..

ATTD 是一个重要的全球会议，专注于糖尿病护理技术的创新。该会议将于2025年3月19日至22日在荷兰阿姆斯特丹举行。

“We are pleased to be showcasing these significant results from our first-in-human trial, demonstrating the safety, feasibility and promising performance of our CBGM,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “This ground-breaking study supports our approach to measuring glucose directly from the blood, rather than interstitial fluid, which enables real-time glucose monitoring with potentially greater accuracy and without on-body wearables, representing a potentially transformative advancement in diabetes management.

“我们很高兴展示来自我们首次人体试验的这些重要成果，证明了我们的CBGM的安全性、可行性和令人鼓舞的表现，”Glucotrack总裁兼首席执行官保罗·V·古德博士说道。“这项突破性的研究支持了我们直接从血液中测量葡萄糖的方法，而非组织间液，从而实现潜在更准确的实时葡萄糖监测，并且无需佩戴在身上的设备，这代表了糖尿病管理领域一项可能带来变革的重大进步。”

We look forward to sharing detailed findings from this important study at ATTD and advancing our clinical program with our upcoming chronic implant study.”.

我们期待在ATTD上分享这项重要研究的详细结果，并通过我们即将进行的慢性植入研究推进我们的临床项目。

The poster will be presented at the meeting and will be made available on the Glucotrack website following the conference.

海报将在会议期间展示，并在会议结束后发布于Glucotrack网站上。

Poster Title:

海报标题：

Early Feasibility Study to Evaluate an Intravascular Continuous Blood Glucose Monitor in Adults with Diabetes Mellitus

早期可行性研究评估糖尿病成人患者体内连续血糖监测仪的效果

Unlike traditional continuous glucose monitors, the CBGM is a long-term implantable device with no on-body external component, designed for three years of continuous, accurate blood glucose monitoring, offering a more convenient and less intrusive glucose monitoring solution.

与传统的连续血糖监测仪不同，CBGM 是一种长期可植入设备，没有体外组件，设计用于三年连续、准确的血糖监测，提供更方便、更少干扰的血糖监测解决方案。

The Glucotrack Continuous Blood Glucose Monitor is an Investigational Device and is limited by federal (or United States) law to investigational use.

Glucotrack连续血糖监测仪是一种研究性设备，根据联邦（或美国）法律，仅限于研究使用。

For more information about Glucotrack’s CBGM technology, visit

有关 Glucotrack 的 CBGM 技术的更多信息，请访问

glucotrack.com

glucotrack.com

. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.

公司网站上的信息不构成本新闻稿的一部分，也不通过引用并入本新闻稿。

About Glucotrack, Inc.

关于Glucotrack公司

Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.

Glucotrack, Inc.（纳斯达克股票代码：GCTK）专注于为糖尿病患者设计、开发和商业化新型技术。该公司目前正在开发一种适用于糖尿病患者的长期可植入连续血糖监测系统。

Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. For more information, please visit

Glucotrack的CBGM是一种长期可植入系统，可持续测量血糖水平，传感器寿命长达3年，无需佩戴外部组件且几乎不需要校准。欲了解更多信息，请访问。

http://www.glucotrack.com

http://www.glucotrack.com

.

。

Forward-Looking Statements

前瞻性声明

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements.

本新闻稿包含1995年《私人证券诉讼改革法案》所指的前瞻性陈述。本新闻稿中非历史事实的陈述可能被视为前瞻性陈述。在不限制前述内容的一般性的情况下，“相信”、“预期”、“计划”和“将”等词语旨在识别前瞻性陈述。

Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

这些前瞻性陈述基于管理层的信念，以及管理层所做的假设和目前可获得的信息。这些陈述仅与作出陈述之日的事件相关，Glucotrack 没有义务公开更新任何前瞻性陈述，无论是由于新信息、未来事件或其他原因，除非法律要求。

All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations.

本新闻稿中所有的前瞻性声明均受这些警示性声明的限制，无法保证 Glucotrack 预期的实际结果将会实现，即使基本实现，也无法保证其对我们或我们的业务或运营产生预期的影响或效果。

Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S.

读者应注意，某些重要因素可能会影响 Glucotrack 的实际结果，并导致这些结果与本新闻稿中可能做出的任何前瞻性陈述存在重大差异。可能影响 Glucotrack 结果的因素包括但不限于 Glucotrack 获得额外资本以资助其运营的能力（无论是通过公开或私人股权融资、债务融资、战略协作或其他方式）；与获得（及时间安排）监管批准相关的风险（包括美国的监管批准）。

Food and Drug Administration approval); ri.

食品药品监督管理局批准）；里。

Contacts:

联系人：

Investor Relations:

投资者关系：

investors@glucotrack.com

投资者@glucotrack.com

Media:

媒体：

GlucotrackPR@icrinc.com

GlucotrackPR@icrinc.com